In a recent issue of Bone Marrow Transplantation, Courbiere et al. 1 raised the possibility of leukemia relapse after autologous transplantation of cryopreserved ovarian tissue from leukemic cell contamination in the graft. They detected a small copy number of Bcr-Abl transcripts by RQ-PCR in the ovarian tissue from an 18-year-old woman with CML. We agree that ovarian transplantation could be proposed (once patients are informed of the risk of leukemia relapse), as there were few contaminating leukemic cells and a GVL effect may be protective.
In Japan, cryopreservation of ovarian tissue is not available, but two other strategies are used to preserve fertility in young women undergoing hematopoietic SCT. One is embryo or oocyte cryopreservation for women with or without a partner, respectively. Although the success rate after transfer of thawed fertilized oocytes had been low previously, both post-thaw survival and fertilization rates of frozen oocytes 2,3 have improved. Nonetheless, concern remains regarding the potential for chromosomal aneuploidy or other karyotypic abnormalities in the offspring, as cryopreservation may affect the meiotic spindle of oocytes. 4 In addition, it is generally difficult to obtain good-quality oocytes from patients receiving chemotherapy. 5 Another strategy is ovarian shielding in women undergoing TBI. Whereas ovarian recovery is observed in only 10-15% of patients receiving standard conditioning with CY and TBI, 6 most patients show ovarian recovery after high-dose CY alone. 6 Ovarian function can therefore be preserved by reducing the radiation dose to the ovaries. We previously reported that ovarian function was recovered in about 80% of patients who underwent ovarian shielding. 7, 8 The incidence of leukemia relapse may not increase if this procedure is performed in patients in remission, as the total radiation dose to the ovaries was approximately 3 Gy in this protocol, which is higher than the TBI dose (2 Gy) in the non-myeloablative regimen of the Seattle group associated with a relapse rate similar to that of a myeloablative regimen. 9 However, a large number of patients is required to determine the actual change in the incidence of relapse under ovarian shielding.
To overcome the difficulty for both physicians and patients in deciding whether or not to perform ovarian shielding, we have used a decision analysis approach. We constructed a decision tree using TreeAge Pro 2009 software (Williamstown, MA, USA) ( Figure 1 ). The square at the left represents a decision node. We can decide either to perform ovarian shielding or not. Circles represent chance nodes and each chance node has 2 or 3 possible outcomes with a specific probability, called the transition probability. Every branch finally ends with triangles, called terminal nodes, and each terminal node has an assigned payoff value, called utility, according to different health states. Calculations were performed backward, from right to left in the decision tree. The sum of the products of transition probabilities and the utilities of the branches becomes the expected value for each chance node, and eventually the sum of the expected values in all of the chance nodes following the decision nodes becomes the expected value of each decision. To make a simple decision model, we determined the transition probabilities based on data from patients who underwent allogeneic transplantation for acute leukemia in first remission. The incidences of transplant-related mortality and relapse were assumed to be 0.2 (20%). 10 However, the incidence of relapse may increase with ovarian shielding ('relapse after ovarian shielding' in Figure 1) . Therefore, while the cure rate is '1-0.2À0.2 ¼ 0.6 (60%)' after a decision to not perform ovarian shielding, it is '1-0.2-relapse after ovarian shielding' after a decision to perform ovarian shielding. The probability of ovarian recovery was determined to be 10% after a decision to not perform ovarian shielding and 80% after a decision to perform ovarian shielding based on the literature. 6,7 Each patient's view of life can be reflected in the value of 'alive without ovarian recovery'. Under the simple assumption that the payoff values of transplantrelated mortality and relapse were both 0 points and the payoff value of cure with ovarian recovery is 100 points, each patient can score the payoff value for 'alive without ovarian recovery' based on her own view of life. Patients for whom ovarian recovery is very important assign a low payoff value for 'alive without ovarian recovery'.
The expected values for the decisions vary according to the values of 'relapse after ovarian shielding' and 'alive without ovarian recovery'. For example, if we fix the value of 'relapse after ovarian shielding' at 30% under the assumption that the incidence of relapse is increased by 10% under ovarian shielding, the expected values for the two decisions vary according to the value of 'alive without ovarian recovery', as shown in Figure 2a (one-way sensitivity analysis). The expected value for a decision to not perform ovarian shielding is higher than that to perform ovarian shielding when a patient scores 'alive without ovarian recovery' higher than 77.3 points. If we fix the value of 'relapse after ovarian shielding' at 40%, the expected value for a decision to not perform ovarian shielding is higher than that to perform ovarian shielding when a patient scores 'alive without ovarian recovery' higher than 56.5 points.
These two values can be changed simultaneously, as shown in Figure 2b (two-way sensitivity analysis). The threshold of the relapse rate, at which there is a change in which decision is made, can be obtained by drawing a vertical line from the 'alive without ovarian recovery' value for each patient. For example, if a patient scores 50 points for the payoff value of 'alive without ovarian recovery', the expected value for a decision to not perform ovarian shielding is higher than that to perform ovarian shielding when 'relapse after ovarian shielding' is higher than 43%, as the vertical line from the X-axis at 'alive without ovarian recovery' of 50 points crosses the borderline of the gray and white areas at 'relapse after ovarian shielding' of 43%.
Although this decision analysis is not definitive, it may be helpful for patients who find it difficult to make a decision when faced with uncertainty. Some young female patients tend to overestimate the value of fertility in their subsequent life, and we should inform patients that they can become pregnant using a donated oocyte even after their ovarian function is lost. Figure 2 One-way (a) and two-way (b) sensitivity analyses. In the gray area, the expected value of a decision to perform ovarian shielding is higher than that of a decision to not perform ovarian shielding.
